Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Pleased with the outcome. It will be interesting to see whether the recent announced licencing agreements have any impact on the share price now that the deal is not going ahead with Global Hemp.
Dr Stephen D Barnhill, CEO and Chairman of Apollon Formularies, commented: "Whilst the Disposal to GHG has now been terminated, the Company continues to retain all of its Assets and the Company is well placed to continue to grow its business globally. We are extremely pleased with our recent Exclusive License Agreement with PureCann Pty Ltd, as announced 24 July 2023. PureCann has already reached impressive commercial milestones allowing us to immediately expand the "Apollon" Brand with our full medical product portfolio for multiple medical conditions into South Africa through their network of dispensaries as well as in their proposed treatment facilities." Dr Barnhill continued: "The Company is currently in discussions with additional companies in multiple countries also looking to license the Apollon intellectual property and products. We look forward to continuing to expand the Apollon brand into additional markets globally."
The Directors of the Company accept responsibility for the contents of this announcement.
For additional information, please visit www.apollon.org.uk or contact:
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international pharmaceutical company trading on the AQSE Growth Market, that is licenced to research, develop, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision, announces that the Company will not be proceeding with proposed deal with Global Hemp Group Inc. ("GHG") under the binding letter of intent ("LOI") released on the 12th of January 2023
As announced on 12 January 2023, under the terms of the binding LOI dated January 9, 2023, GHG acquired the exclusive perpetual license for North America (specifically, the United States, Canada. and Mexico) to certain Apollon Intellectual Property and proprietary technology, for US$250,000 and 10,000,000 common shares in GHG. On April 4, 2023 GHG announced that it completed its contractual payment obligations relating to the Exclusive Licensing Agreement for the patents and Intellectual Property ("IP") of Apollon. On March 21, 2023, GHG announced that the Company added additional exclusive licenses from Apollon for the countries of Israel, and the European Union (with extension to Morocco).
Apollon expects to benefit from the Licensing Fee revenues which shall equal 10% of gross sublicensing fees received by GHG. During the term of this License Agreement, GHG shall pay a quarterly licensing fee to Apollon, the payment of which shall be triggered when revenues are first generated from sublicensing activities. Payment of the Licensing Fee shall commence in the subsequent quarter as agreed to in the License Agreement dated January 19, 2023, emanating from all gross sublicensing fees received by GHG in North America (the United States, Canada, and Mexico), the European Union with extension to Morocco and Israel. In addition, under the LOI, a due diligence period was allowed and if both the Company and GHG were satisfied, GHG would have the exclusive option to acquire all the assets of Apollon, other than cash, cash equivalents, and receivables, for a payment of 771,191,266 GHG common shares at a deemed price of $0.015 per GHG common share, for a total consideration of C$11,567,869 ("Disposal"). The Disposal has been terminated by mutual consent.
Dr Stephen D Barnhill, CEO and Chairman of Apollon Formularies, commented: "Whilst the Disposal to GHG has now been terminated, the Company continues to retain all of its Assets and the Company is well placed to continue to grow its business globally. We are extremely pleased with our recent Exclusive License Agreement with PureCann Pty Ltd, as announced 24 July 2023. PureCann has already reached impressive commercial milestones allowing us to immediately expand the "Apollon" Brand with our full medical product portfolio for multiple medical conditions into South Africa through their network of dispensaries as well as in their proposed treatment facilities." Dr Barnhill continued:
Outlook
Looking ahead, we are optimistic about the future of Apollon Formularies. We remain committed to advancing our pipeline of innovative natural biologic products, expanding our global footprint, and delivering sustainable long-term growth. We continue to invest in research and development, patent protecting our discoveries, and leveraging cutting-edge artificial intelligence technologies and scientific advancements to develop breakthrough therapies that address unmet medical needs.
We are excited to have completed and filed the necessary national phase patent application through the PCT in the following territories: the US, Canada, Mexico, Israel, and the European Union with extension to Morocco and South Africa. The Group also has patent applications pending in Jamaica. These patent applications have resulted in significant upfront licencing fees and should continue to provide revenue to Apollon through product royalties. We continue to negotiate with additional potential licencees for additional expansion of our intellectual property rights and product sales globally.
We also look forward to the final decision from GHG on its due diligence.
Https://polaris.brighterir.com/public/apollon_formularies/news/rns/story/rgzm3zw
Https://polaris.brighterir.com/public/apollon_formularies/news/rns/story/x5voqpw
Extract
Apollon Formularies Plc
Apollon grants an Exclusive Licence Agreement to PureCann, South Africa
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, is pleased to announce that it has signed an Exclusive License Agreement with PureCann Pty Ltd. ("PureCann"), a South African based medical cannabis company, which will produce, and actively distribute the entire Apollon product range throughout their dispensary network currently being rolled out in South Africa. The license includes the rights to distribute Apollon proprietary medicinal products to the Southern African Development Community (SADC) and throughout the African continent where medical cannabis is legally available once the relevant export licenses have been secured by PureCann for these regions.
Transaction Highlights:
-- Apollon will receive a once off licensing fee of £100’000 as well as an
ongoing royalty of 6% of gross profit on sales by PureCann for the
entire term of the licence.
-- Apollon grants PureCann an Exclusive Licence which gives PureCann the
rights to Apollon’s Patent applications, Proprietary Formulations,
Patient Protocols and access to the technology relating to formulations
which showed successful cancer cell killing in the BIOENSIS pre-clinical
studies.
-- Apollon will benefit from brand exposure and sales royalties in
PureCann’s licensed medical cannabis dispensaries as well as PureCann’s
treatment facilities planning on being rolled out in Q4 of 2023.
-- Further Sub-Licence revenue will be applicable at a commercially
favourable split between Apollon and PureCann where PureCann are able to
enter into sub license agreements with the other nine African countries
where medicinal cannabis is legally available to patients in those
jurisdictions under a Sales and Distribution agreement along with
further jurisdictions which may legalise in the term of this licence
agreement.
-- Apollon will also benefit from crucial clinical data and royalties
generated from PureCann’s Treatment centre in Cape Town, South Africa in
the near future.
1 | P a g e
ASX ANNOUNCEMENT
18 May 2023
Drilling Underway at Bynoe Lithium Project
Maiden reverse circulation (RC) drill programme has commenced at the Bynoe Lithium
Project, NT
Initial ~2,000m programme has been designed as a first-pass test of high priority targets
including the Megabucks, Old Bucks and Enterprise prospects
The programme is expected to take approximately three weeks
Charger Metals NL (ASX: CHR, “Charger” or the “Company”) is pleased to announce that drilling
has commenced at the Bynoe Lithium Project, Northern Territory.
Charger’s Managing Director, Aidan Platel, commented:
“We are thrilled to have commenced our maiden drill programme at our exciting Bynoe Lithium
Project. The first-pass programme will drill test priority targets at the Old Bucks, Megabucks and
Enterprise Prospects, all of which are located in a structural corridor directly along strike from Core
Lithium Limited’s (ASX:CXO) operating Finniss Lithium Mine. 1
Samples will be submitted to a certified laboratory in Darwin on a regular basis and we look forward
to updating the market as the assay results come to hand.”
This sounds positive:
https://www.sportsbusinessjournal.com/SB-Blogs/SBJ-Power-Up/2023/04/12.aspx
NHL, Low6 strike official partnership on free-to-play games
The NHL has made Low6 an official free-to-play gaming provider after the U.K.-based company successfully created several offerings for the league since it debuted "NHL PrePlay" last December.
As part of the new multiyear deal, the NHL has made a strategic investment in Low6, which last year raised $5 million and found success in the collegiate space through a pact with Learfield.
For the NHL, free-to-play games like the ones from Low6 help create a second screen interactive experience to attract more hockey fans, the most recent being its postseason Bracket Challenge.
Other NHL-Low6 games recently launched include NHL Stats Streak, NHL Winter Classic, NHL Stadium Series, NHL All-Star Bingo and the 2023 NHL All-Star Fan Vote. In addition to the bracket challenge, a 2023 Stanley Cup Final Bingo game is set to be released this spring.
Very positive news announced today;
https://www.investegate.co.uk/gunsynd-plc--gun-/rns/pacific-nickel---nickel-project-update/202304051307245146V/
https://twitter.com/Low6Lowdown/status/1642812667537641474/photo/1
Due in the next 2 days. From the previous RNS:
The Company has made good progress in conjunction with its auditor to resolve the issues presented in the Company’s report and accounts for the year ended 31 December 2021 and is on track to release its results for the year end for September 30, 2023, in advance of the March 31, 2023 deadline.
Counting down to the results now and expecting a significant improvement over the same period the previous year.
Starting a long climb back up after the recent director share purchase...up 40% today so far.
It would appear the director buy has sparked some further interest here. Can't be many shares available given the 1.379p buy yesterday for 216k shares.
Life in the old dog yet....
Can buy online again.
With a discount of circa 73% to NAV, I am anticipating a decent correction when the interims are released next month which will hopefully show a cash flow positive situation and being profitable at the operational level.
Having £2.5m in the bank also helps.
Not sure what is going on here, but there has been an error message when trying to buy shares online through Interactive Investors. Managed to buy more with a telephone trade.
Now a huge discount to NAV and with the interims due in March, which should be a whole lot better, perhaps we may get back to a sensible valuation.
Worth reading the full announcement from GKN with specific reference to the integration of the low voltage and high voltage electrical interconnections. Pretty sure that is what GKN and Trackwise have been developing for the last 5 years.
https://www.gknaerospace.com/en/newsroom/news-releases/2023/lilium-joins-forces-with-gkn-aerospace-for--lilium-jets-electrical-wiring-interconnection-system-ewis/